Since the beginning of the HIV epidemic, cancer has figured prominently in the spectrum of immunodeficiency-related manifestations. In particular, the risk of Kaposi sarcoma and non-Hodgkin's lymphoma (NHL) is vastly higher among HIV-infected persons than in healthy persons [e.g., standardized incidence ratios (SIRs) of 20 000–50 000 and 50–80, respectively, comparing risk among people with AIDS in the United States to risk in the general population] . Cervical cancer risk is also elevated among HIV-infected women, though to a lesser degree (i.e., SIRs 4–8) . These three malignancies are considered 0002030-defining conditions by the US Centers for Disease Control and Prevention . All three are caused by oncogenic viruses, namely human herpesvirus 8 for Kaposi sarcoma; Epstein–Barr virus (EBV) for the two most common 0002030-associated NHL subtypes, diffuse large B cell NHL and central nervous system NHL; and human papillomavirus (HPV) for cervical cancer [3,4].
A major feature of these cancers in HIV-infected persons is their association with immunosuppression. For Kaposi sarcoma and EBV-related NHL subtypes, risk increases as the CD4 cell count declines . This association with CD4 cell count has not been apparent for cervical cancer , though HIV-infected women with low CD4 cell counts have an elevated risk of persistent HPV infection and progression to precancerous cervical lesions, compared with women with higher CD4 cell counts . Risk of all three 0002030-defining malignancies is also elevated among solid organ transplant recipients, another immunosuppressed population .
In developed countries, the availability of highly active antiretroviral therapy (HAART) beginning in 1996 has led to improvements in immunity and declining 0002030-related morbidity and mortality [8–10]. HAART substantially reduces the risk of Kaposi sarcoma and EBV-related NHL [11–13]. For unknown reasons, Kaposi sarcoma and NHL incidence rates were falling even during the 1980s and early 1990s among people with AIDS in the United States, but introduction of HAART in 1996 led to a further drop (Fig. 1) . As a result of these declines, non-0002030-defining malignancies now represent a much larger fraction of the overall cancer burden in people with AIDS compared with the pre-HAART era (Fig. 1) . Among less immunocompromised HIV-infected persons, non-0002030-defining cancers now comprise the majority of all incident cancers (e.g., in the United States: 58% of all cancers vs. 31% in the pre-HAART era) .
This review considers the epidemiology of several major non-0002030-defining cancers in HIV-infected persons. The focus is on malignancies for which HIV-infected persons have an elevated risk, for which risk is substantial or may increase over time, and for which HIV infection may play an etiologic role in the development of the cancer. The review does not focus on common cancers for which risk is not elevated in HIV-infected persons compared with the general population or for which evidence of an increase is inconclusive (e.g., colon cancer) , though these cancers represent an important cause of morbidity. Most attention will be directed at cancer in developed countries in the West, because it is these countries where HAART has been most widely available and for which most epidemiologic data exist.
Non-0002030-defining malignancies: epidemiologic pieces of the etiologic puzzle
Clinicians caring for HIV-infected people increasingly recognize a diverse group of non-0002030-defining cancers as important sources of morbidity and mortality. Many of these malignancies are due to chronic infections with oncogenic viruses [e.g., liver cancer related to chronic hepatitis C and B viruses (HCV and HBV), anogenital cancers related to HPV]. Others arise from tobacco (e.g., cancers of the lung, head and neck, bladder) and alcohol abuse (e.g., cancers of liver and head and neck), which are common problems in HIV-infected populations in North America and Europe.
Five of these non-0002030-defining cancers deserve special attention and will be highlighted in this review (Table 1). These malignancies (lung cancer, Hodgkin's lymphoma, anal cancer, liver cancer, and nonmelanoma skin cancers) are among the most common among HIV-infected persons, and each arises at increased frequency compared with the general population . As will be described, a concerning aspect of the epidemiology is that for two of the malignancies (Hodgkin's lymphoma and anal cancer), incidence among HIV-infected persons has been increasing in the HAART era.
As reviewed below, the epidemiologic data suggest that HIV may facilitate, at least indirectly, the development of these non-0002030-defining cancers. For Hodgkin's lymphoma, HIV-infected persons present more frequently with extranodal disease and at an advanced stage than HIV-uninfected individuals . In contrast, data are lacking for carcinomas on whether the phenotype (e.g., histologic subtype, molecular tumor characteristics, or potential to metastasize) differs in any essential way from the phenotype of tumors in uninfected individuals. For lung cancer and liver cancer, HIV-infected individuals tend to present at a more advanced stage than uninfected individuals [17–20], but this difference could be secondary to poor access to medical care and delayed diagnosis. Likewise, lung cancers in HIV-infected individuals manifest greater genetic instability than those in uninfected persons , but this characteristic could merely reflect the advanced stage of the tumors. Prognosis among HIV-infected cancer patients is typically worse than in uninfected cancer patients [17,20,22], which plausibly could reflect advanced stage of cancer diagnosis, differences in cancer treatment, and 0002030-related mortality. One intriguing exception in which HIV infection may alter the phenotype is nonmelanoma skin cancer. Immunosuppressed solid organ transplant recipients have a greatly elevated risk for developing multiple, highly aggressive squamous cell skin cancers , and similar cases have been described in HIV-infected persons [24,25].
A reasonable working hypothesis is therefore that non-0002030-defining malignancies in HIV-infected persons are not pathologically distinct entities. Rather, these tumors represent the same cancers as seen in uninfected individuals, but they occur at an increased rate among HIV-infected persons. This increased incidence could, in turn, reflect a high prevalence of known cancer risk factors, an independent effect of HIV on progression to cancer, or a biological interaction of HIV with the known risk factors. The following sections review the epidemiologic data and consider some potential biological mechanisms whereby HIV might facilitate development of these malignancies.
Lung cancer is the most common non-0002030-defining malignancy among HIV-infected individuals in developed countries . Risk is elevated for all major lung cancer subtypes (adenocarcinoma, squamous cell carcinoma, and small cell carcinoma) [18,26]. The high risk of lung cancer partly relates to a high prevalence (40–70%) of tobacco use among HIV-infected individuals [27–29], and almost all lung cancer cases occur in smokers [11,26,30]. However, lung cancer risk is also increased in immunosuppressed transplant recipients , a group in which smoking is not especially common. Furthermore, recent studies suggest that the elevated risk among HIV-infected persons cannot be entirely explained by their frequent tobacco use [18,26,31]. These studies have limitations, because it has been challenging to obtain detailed smoking data from a large enough HIV-infected population to reliably estimate cancer risk. Nonetheless, under plausible assumptions, the recent analyses suggest that lung cancer risk is three to four times higher in HIV-infected persons than in uninfected persons after adjustment for smoking intensity and duration [18,26,31].
Lung cancer can develop at any point in the course of HIV disease, though risk increases somewhat in the periods immediately before AIDS and subsequent to an AIDS diagnosis . Lung cancer risk is not closely related to CD4 cell count or HIV viral load [18,26,31]. Data on whether HAART use is associated with a decrease in lung cancer risk are conflicting [11,15,26,31], but lung cancer incidence has not declined noticeably in recent years as HAART has become widely available and increasingly used [15,18,26,31].
Hodgkin's lymphoma risk is substantially elevated among immunosuppressed HIV-infected persons and transplant recipients [7,32]. Most Hodgkin's lymphoma cases are of the mixed cellularity subtype [16,32,33], in distinction to a predominance of nodular sclerosis subtype seen in young adults in the general population. In Hodgkin's lymphoma, the malignant cell is the Hodgkin Reed–Sternberg cell, a transformed B lymphocyte that comprises only a small minority of the tumor cell population; the remainder of lesional cells constitute a population of nonmalignant immune and stromal cells supported by cytokines and other cell signals from the Hodgkin Reed–Sternberg cell [34,35]. In immunocompromised persons, Hodgkin Reed–Sternberg cells are almost always EBV positive [16,36], suggesting that the increased risk of Hodgkin's lymphoma in HIV-infected persons is due to loss of control of EBV infection. In accord with a model in which loss of immune control of latent EBV infection leads to Hodgkin's lymphoma, Hodgkin's lymphoma risk among HIV-infected persons rises following an AIDS diagnosis .
Nonetheless, the relationship between immunosuppression and development of Hodgkin' lymphoma is complex. Paradoxically, in light of the likely involvement of EBV, Hodgkin's lymphoma risk increased during the 1990s among HIV-infected persons (Fig. 2, panel a) [1,14,15,38], during a period when HIV therapy became increasingly effective and should have led to improved immune control of EBV infection. It is likewise surprising that Hodgkin's lymphoma risk in persons receiving HAART appears similar to or higher than that in HIV-infected persons not on HAART [11,33]. Additionally, among HIV-infected persons, the association between CD4 cell count and Hodgkin's lymphoma risk has a nonlinear ‘inverted U’ shape (Fig. 2, panel b) . Specifically, Hodgkin's lymphoma risk increases with a decline in CD4 cell count to 225–249 cells/μl but then falls again as the CD4 cell count declines further.
Anal cancer is caused by persistent infection with oncogenic subtypes of HPV . Anal cancer incidence is especially high in HIV-infected men-who-have-sex-with-men  due to sexual transmission of HPV through anal intercourse. In this group, anal HPV infection is almost universal, chronic, and frequently characterized by the presence of multiple HPV subtypes [41,42]. Anal cancer incidence is also elevated among other HIV-infected men and women , which could partly reflect acquisition of HPV through anal sex, but also probably reflects indirect transmission of HPV related to other sexual acts (i.e., transfer of HPV from genital sites) .
The role of HIV-related immunosuppression in promoting development of anal cancer has been somewhat difficult to establish. With HIV, detection of anal HPV increases with declining CD4 cell count , likely as a result of decreasing clearance of HPV with immunosuppression. Likewise, the risk for anal cancer precursor lesions (i.e., anal intraepithelial neoplasia) rises with decreasing CD4 cell count among HIV-infected individuals [41,43,44]. Further pointing to the importance of HIV-induced immunosuppression, recent research indicates that the incidence of anal cancer is inversely related to CD4 cell count and increases following an AIDS diagnosis [45,46], though these associations were not seen in the pre-HAART era . Anal cancer incidence is also elevated among solid organ transplant recipients . Finally, chronic inflammation may also be important in promoting the development of anal cancer , though the effects of HIV on modulating this process are unknown.
Given these findings implicating immunosuppression, one might have predicted a decline in anal cancer incidence with introduction of HAART in 1996. However, a number of epidemiologic studies have found either a stable or increasing occurrence of anal cancer since the advent of HAART [1,15,45,46,48]. Data are conflicting with regard to the prevalence, persistence, and regression of anal intraepithelial neoplasia in relation to HAART use . Perhaps most surprising, anal cancer incidence appears higher in persons who actually use HAART compared with HIV-infected individuals not receiving HAART [11,45,48].
In HIV-infected persons, an excess risk of liver cancer (specifically hepatocellular carcinoma) is largely attributable to frequent coinfection with HCV (e.g., in the United States, 70–95% prevalence among HIV-infected individuals with blood exposures, such as injection drug users and people with hemophilia) and HBV (5–15% prevalence across HIV risk groups in the United States) . Most HIV-infected liver cancer patients are chronically coinfected with one of these two viruses [19,20,51]. Cirrhosis is often present at the time of liver cancer diagnosis .
Of interest, the excess risk for liver cancer associated with HCV is more modest among HIV-infected persons than observed in HIV-uninfected persons (i.e., relative risks 2–7 vs. approximately 12) [51,53–55]. This apparent difference in risk conveyed by HCV coinfection could reflect a shorter duration of HCV infection among HIV-infected persons than in the general population, or the effects of HIV in driving progression to end-stage liver disease, which could lead to additional mortality that might partly mask an increased risk of liver cancer [19,20,51,53,56,57]. Among HBV-infected persons, liver cancer risk increases with rising HBV replication , so risk would be expected to be high among immunodeficient HIV-infected individuals who fail to control HBV .
Nonetheless, the effect of HIV infection itself on liver cancer risk has been somewhat uncertain. One study of US military veterans found no difference in liver cancer risk between HCV-infected and HCV–HIV-coinfected individuals , suggesting that HIV-related immunosuppression does not play an important role. In contrast, a recent study demonstrated an increase in liver cancer risk among HIV-infected persons associated with declining CD4 cell count, particularly for HBV-related liver cancer . Although some antiretroviral medications can manifest liver toxicity, limited data suggest that HAART use may decrease liver cancer risk [51,61], perhaps due to improved immune control of viral hepatitis.
Finally, though alcohol abuse is prevalent among HIV-infected persons, its effect on liver cancer risk has not been measured. A history of alcohol abuse is less common among HIV-infected liver cancer cases than among uninfected cases [19,52], suggesting that alcohol abuse may have a modest effect on risk.
Nonmelanoma skin cancers
Nonmelanoma skin cancers are a heterogeneous group of malignancies . Chronic exposure to solar ultraviolet light is the major risk factor for all skin cancer subtypes, and their incidence is much greater in non-Hispanic whites (who lack protective skin pigmentation) than other racial/ethnic groups [63,64]. Basal cell and squamous cell carcinomas are the most common skin cancer subtypes in the general population and are typically associated with a good prognosis following local excision . Unfortunately, most cancer registries do not record the occurrence of these two skin cancer subtypes, which has complicated epidemiologic research.
Despite limitations in available epidemiologic data, it is apparent that immunosuppressed transplant recipients have an elevated risk of basal cell and, especially, squamous cell skin cancers [23,65]. Limited data for HIV-infected individuals also show an elevated risk of squamous cell and basal cell skin carcinomas , perhaps rising over time . Additionally, published case series describe the occurrence in HIV-infected persons (as in transplant recipients) of unusually aggressive squamous cell skin cancers [24,25,68,69]. To a lesser extent, melanoma risk also appears increased in HIV-infected persons and transplant recipients [7,15,70], which could relate to immunosuppression but may instead be artifactual (e.g., resulting from heightened medical surveillance).
Notably, HIV-infected individuals and transplant recipients have a markedly elevated risk for two rare subtypes of nonmelanoma skin cancer, Merkel cell carcinoma and sebaceous carcinoma (SIRs 11 and 8, respectively, among people with AIDS) . A novel polyomavirus was recently identified in Merkel cell carcinoma tumors .
Of final interest, the occurrence of the various subtypes of nonmelanoma skin cancers in HIV-infected persons is largely limited to non-Hispanic whites [25,69,70]. Similarly, it is striking that in a follow-up study of kidney transplant recipients in South Africa , only whites developed nonmelanoma skin cancers, despite the fact that the majority of recipients were nonwhite; most of the diagnosed skin cancers were squamous cell or basal cell carcinomas, though one case was an appendageal carcinoma. These observations highlight the continued importance of sun exposure even in the setting of immunosuppression.
It may be debated whether nonmelanoma skin cancers deserve the same consideration as the other non-0002030-defining malignancies evaluated in this review. Data are limited regarding risk for the most common nonmelanoma skin cancer subtypes (squamous and basal cell carcinomas), whereas other subtypes potentially linked to oncogenic viruses (e.g., Merkel cell carcinoma and perhaps sebaceous carcinoma) are quite rare. Nonetheless, the available data for HIV-infected individuals and the clear excess risk in solid organ transplant recipients suggest that these cancers may be an under-recognized source of morbidity, especially in non-Hispanic whites.
Immunologic mechanisms: possible new paradigms for HIV-related carcinogenesis
The importance of the established risk factors for these five non-0002030-defining malignancies (e.g., tobacco, HPV, sunlight; Table 1) cannot be denied. Furthermore, it seems unlikely that HIV-infected persons who lack these exposures are at substantial risk for the cancers. Nonetheless, it would be inappropriate to conclude that HIV is unimportant in the etiology of these non-0002030-defining malignancies. This situation is similar to that for 0002030-defining conditions, in which the presence of additional agents is required for their development. Rather, the relevant question is: in the presence of certain known carcinogens, does HIV infection amplify the effects of these carcinogens to promote development of cancer? The most obvious mechanism by which HIV could facilitate the development of these malignancies is by disturbing the host immune system. Consideration of the epidemiologic evidence and other recent data presented above suggests that several immunologic mechanisms could be involved in the etiology of these malignancies (Table 2).
The simplest immunologic mechanism to consider is HIV-induced depletion of CD4 cells, leading to deficient cell-mediated immunity. This mechanism is highly relevant for Kaposi sarcoma and NHL . The epidemiologic hallmarks of this mechanism are strongly increased risk of cancer compared with the general population and clear-cut associations with markers of immunosuppression, such as CD4 cell count, time relative to AIDS onset, and the protective effects of HAART. Another hallmark is an elevated risk for the cancer among transplant recipients, who receive chronic immunosuppressive therapy to prevent graft rejection. It has been hypothesized that an intact immune system can control or eliminate early cancer precursor cells, protecting against a wide range of cancers (i.e., the immune surveillance hypothesis ). Nonetheless, evidence in HIV-infected persons and transplant recipients is strongest that immunodeficiency predisposes to the subset of malignancies caused by oncogenic viruses, likely because of loss of immune control of viral replication and transformation. Regarding the non-0002030-defining cancers highlighted in this review, this mechanism may be most relevant for some nonmelanoma skin cancers, particularly the rare subtypes such as Merkel cell carcinoma and sebaceous carcinoma, in which oncogenic viruses could have a direct transforming role. Although limited data on these skin cancers preclude a definitive assessment, the substantially increased risk compared with the general population, in the absence of another obvious explanation, suggests that HIV-related immunosuppression is relevant.
It is useful to speculate on additional immunologic mechanisms related to HIV infection that could potentially play a role in the development of other non-0002030-defining malignancies (Table 2). For anal cancer, there are several salient observations: first, low CD4 cell counts are associated strongly with detection of anal HPV infection and precancerous lesions, but less strongly with risk of anal cancer itself; second, anal cancer risk increases with progressive time relative to an initial AIDS diagnosis; and third, anal cancer incidence has increased during the HAART era and is elevated among individual HAART users. A model that could account for these observations is that HIV-related immunosuppression is relevant at the earliest stages of anal carcinogenesis (such as HPV persistence and development of low-grade anal intraepithelial neoplasia) but not involved in the later progression to invasive cancer . Under such a model, HAART would not result in a benefit if administered after the early steps in this process. Indeed, due to the survival benefits associated with HAART use, persons receiving HAART would live long enough to develop anal cancer. In other words, HAART use increases time spent living with early-stage neoplastic lesions, allowing their progression to invasive cancer. Likewise, the increase in anal cancer risk associated with AIDS onset may not reflect the effects of progressive immunosuppression but rather prolonged time spent living with immunosuppression and duration of HPV-related disease.
Given the rarity of liver cancer, a challenge has been to gather sufficient data to assess the effects of HIV infection and related immunosuppression. One possibility is that deficiency of cell-mediated immunity plays a role in the development of liver cancer by reducing immune control of chronic HCV and HBV infections. However, the situation may be more complicated than for anal cancer. Specifically, for liver cancer, immunosuppression not only predisposes to 0002030-related mortality but also liver-related mortality [56,57,74]. In the pre-HAART era, one or both of these competing causes of mortality may have obscured an association between immunosuppression and liver cancer risk.
The elevated risk of lung cancer in HIV-infected smokers probably has a different explanation, as risk is not strongly related to markers of HIV-related immunosuppression such as CD4 cell count and prior AIDS onset. In addition, risk is elevated for all lung cancer subtypes, pointing away from involvement of a single oncogenic virus (and thus, pointing away from immunosuppression). One possibility is that HIV infection promotes the development of lung cancer by causing chronic pulmonary inflammation and repeated lung infections, which could induce DNA damage in a synergistic manner with tobacco . In the general population, chronic lung infections due to Chlamydia pneumoniae and tuberculosis are linked with an increased risk of developing lung cancer . At all stages of infection, HIV is associated with chronic or repeated lung infections due to microorganisms that frequently cause pneumonia in the general population (e.g., Streptococcus pneumoniae) as well as opportunistic microorganisms (e.g., Mycobacterium avium intracellulare, Pneumocystis jirovecii). HIV infection also leads to expansion of the pool of pulmonary macrophages and elevated levels in the lung of pro-inflammatory cytokines, such as interleukin 1 beta, tumor necrosis factor, and interferon gamma . If HIV amplifies the effects of tobacco by inducing chronic lung inflammation or causing repeated pulmonary insults due to infections, processes that occur at all levels of HIV-related immunosuppression, a strong association of lung cancer risk with CD4 cell count or advanced HIV disease might not be expected.
For Hodgkin's lymphoma, an additional possibility is that some cases arise as part of an immune reconstitution syndrome . This hypothesis is consistent with the nonlinear relationship between CD4 cell count and Hodgkin's lymphoma risk and with rising Hodgkin's lymphoma incidence during the HAART era. Specifically, the increase in CD4 cell count associated with HAART use among extremely immunodeficient individuals may shift them to a level of immunosuppression (i.e., a CD4 cell count 200–250 cells/μl, Fig. 2) that puts them at greatest risk for Hodgkin's lymphoma. In that setting, Hodgkin's lymphoma may develop because the malignant Hodgkin Reed–Sternberg cell may already be present, and partial restoration of immunity allows recruitment of surrounding immune cells and manifestation of the tumor . In other cases, Hodgkin's lymphoma may develop in a more direct manner with progressive or prolonged immunosuppression. The situation may be analogous to what is observed for Kaposi sarcoma, another malignancy in which a substantial component of the lesional cells is not actually malignant. Although Kaposi sarcoma most often arises with progressive loss of cell-mediated immunity, cases with onset or worsening related to HAART-induced immune reconstitution are described [77–79].
In the HAART era, several mechanisms in Table 2 are likely to become increasingly important in the development of cancer. The role of these various mechanisms in the etiology of non-0002030-defining cancers should be evaluated in large, well designed epidemiologic studies. Ideally, the studies should include detailed data on validated cancer cases and extensive longitudinal measurements of CD4 cell count, HIV viral load, and use of antiretroviral medications. Given the rarity of most cancer outcomes, use of pooled data from consortia may be required and, given the complexity of the analyses, replication will likely be necessary.
Finally, it will be important to evaluate the possibility that HIV medications could themselves increase risk for some cancers. A possibility is that some medications may have direct genotoxic effects that initiate or promote development of cancer. For example, zidovudine, a nucleoside reverse transcriptase inhibitor, is incorporated into host DNA and can induce point mutations and chromosomal breaks , but whether these changes translate into an increased cancer risk is unknown. Because patients frequently switch antiretroviral medications and because effects on cancer risk may require years of exposure and follow-up to manifest, it will be extremely challenging to identify whether specific antiretroviral medications cause specific types of cancer.
Prevention, screening, and early detection
Consideration of these non-0002030-defining cancers highlights clinical and public health opportunities (Table 3). Some potential interventions are straightforward extensions of practices for HIV-uninfected persons and would appear to promise substantial reductions in cancer-related morbidity and mortality. However, their utility and cost-effectiveness for HIV-infected individuals are largely unknown. Detailed evaluation of available and, in some instances, improved strategies will be important before they can be adopted as routine practice.
Counseling by clinicians will play a role in prevention programs. The cornerstone of prevention for lung cancer is tobacco cessation, and, given the role of tobacco in other illnesses, programs to encourage HIV-infected individuals to quit smoking should be a priority. Although counseling and available pharmacotherapy are helpful , development of more effective interventions in smoking cessation, including those targeted specifically at HIV-infected persons, will be important. Encouraging HIV-infected people to limit the number of their sexual partners may reduce their risk of acquiring new HBV and HPV infections, but condom use is of unproven benefit (e.g., for anal HPV ). For individuals with liver disease, abstinence from alcohol may help prevent progression to liver cancer. Finally, encouraging HIV-infected persons to minimize unnecessary sun exposure is prudent to reduce skin cancer risk.
Vaccination strategies may also help prevent cancers. HBV vaccination prevents HBV infection and is associated with reduced occurrence of liver cancer . HBV vaccine is less immunogenic among HIV-infected individuals than healthy persons but should still be offered . A vaccine against HPV subtypes 16 and 18 is available to prevent cervical infection . This vaccine could conceivably prevent anal infections due to these oncogenic subtypes (though this is unproven) and thus might prevent anal cancer . To be effective, HBV and HPV vaccines would need to be administered before acquisition of these infections, which often occurs before acquisition of HIV. Thus, it remains unclear whether vaccination of persons who are already HIV-infected could prevent a sizeable number of liver or anal cancers. Among individuals with chronic liver disease, treatment of HCV and HBV infection may prevent progression to liver cancer .
Screening is targeted at identifying early-stage premalignant lesions, with the goal of eliminating those lesions to prevent progression to cancer. Only two of the non-0002030-defining malignancies in Table 3 have known premalignant lesions that can be detected clinically and are thus amenable to screening intervention. For anal cancer, anal Pap smear screening can detect potentially precancerous anal lesions (i.e., high-grade squamous intraepithelial lesions) that can be ablated with localized therapies . Issues regarding Pap smear screening include the high prevalence of anal intraepithelial neoplasia lesions potentially requiring intervention, uncertainty regarding the natural history of these lesions (i.e., rates of progression from high-grade squamous intraepithelial lesions to cancer), need for repeated screening to detect incident lesions, need for expertise in evaluating and treating premalignant lesions detected by Pap smears, and lack of proven effectiveness in reducing cancer burden . Nonetheless, under a broad range of assumptions, anal Pap smear screening in HIV-infected men-who-have-sex-with-men appears to be cost-effective . Testing of anal specimens for carcinogenic HPV genotypes may also be useful in risk stratification, as is the case for cervical cancer . Skin cancer screening can identify premalignant lesions, such as dysplastic nevi (a precursor to melanoma) and actinic keratoses (a precursor to squamous cell carcinoma). Given the simplicity and low cost of skin cancer screening, it seems feasible to incorporate it into periodic health examinations in HIV-infected persons. As in the transplant setting , HIV-infected patients with prior skin cancers should likely receive more intensive screening by dermatologists. Because the vast majority of skin cancer cases arise in non-Hispanic whites, it is reasonable to focus predominantly on this group.
Early detection has as its aim the detection of cancers at a stage when they are still localized and amenable to cure. The two screening modalities mentioned above, which have as their goal the detection of premalignant anal and skin lesions, would also detect cancers at a localized stage when site-directed treatment might be curative. For high-risk smokers (e.g., those with heavy long-term tobacco use or chronic obstructive pulmonary disease), lung cancer screening through the periodic use of chest radiographs or computed tomography scans can detect localized cancers. Although potentially attractive, such screening is expensive, and these approaches are not yet demonstrated to be effective in the general population [93,94]. Of note, whereas the higher risk of lung cancer in HIV-infected persons compared with uninfected persons increases the cost-effectiveness of screening, possibly lower sensitivity or specificity of diagnostic tests (e.g., due to a high frequency of nonspecific findings on chest radiographs in HIV-infected persons) could reduce cost-effectiveness. Among patients with cirrhosis in the general population, periodic screening for liver cancer with serum alpha-fetoprotein testing and ultrasound has been advocated by some experts , and extension of such screening to HIV-infected persons may be warranted .
As the physicist Niels Bohr said, ‘Prediction is difficult, especially about the future.’ Nonetheless, for three reasons, it is reasonable to predict that the burden of non-0002030-defining cancer morbidity will rise over time in HIV-infected persons. As described above, for at least two cancers, incidence has already increased in recent years, perhaps due to immune-modulating effects of HAART (Hodgkin's lymphoma) or prolonged infection with an oncogenic virus (anal cancer). Second, because HIV-infected persons are now living longer, due to the beneficial effects of HAART, they are aging. Incidence of most cancers rises with age, due to an accumulation of DNA mutations from known carcinogenic exposures (e.g., tobacco smoke), the effects of chronic inflammation (e.g., hepatitis related to HCV infection), as well as from unknown or random events. For virtually all types of cancers – those in which HIV-infected persons are frequently exposed to potent carcinogens, in which HIV exerts an additive effect on risk, even in which risk is the same as in the general population and HIV exerts no effect – the incidence will rise among HIV-infected persons due simply to aging. Third, prolonged survival attributable to HAART will increase the time during which HIV-infected persons are at risk of cancer, thus increasing the number of observed cases. In the absence of competing mortality from AIDS, HIV-infected persons have more opportunity to develop a cancer. It seems possible that these factors will remain relevant even if HAART is initiated at an earlier stage of HIV infection than currently recommended . Thus, the rising number of cases of non-0002030-defining cancers will make prevention and treatment of these malignancies an increasing priority in HIV care.
As we enter the second decade of the HAART era, these considerations point to a need for additional research on the etiology of non-0002030-defining cancers in HIV-infected persons. Ultimately, the goal of this research is to prevent cancer in HIV-infected individuals. By shedding light on immune-related and other pathways, the research may also help clarify the etiology of diverse malignancies in HIV-uninfected people.
This work was supported by the Intramural Research Program of the National Cancer Institute. The views expressed are those of the author and should not be considered as reflecting views or policy of the National Cancer Institute.
I am grateful for helpful comments and suggestions from Drs Anil Chaturvedi and James Goedert at the National Cancer Institute.
1. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006; 20:1645–1654.
2. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.Morb Mortal Wkly Rep
3. IARC Monographs on the evaluation of carcinogenic risk to humans: Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8.International Agency for Research on Cancer
; Lyon, France; 1997.
4. IARC Monographs on the evaluation of carcinogenic risk to humans: human papillomaviruses.International Agency for Research on Cancer
; Lyon, France; 2007.
5. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. 0002030-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962–972.
6. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al
. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577–586.
7. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59–67.
8. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al
. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725–1730.
9. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15:347–355.
10. Sterne JAC, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al
, Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378–384.
11. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al
. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425–432.
12. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al
. 0002030-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. The Swiss HIV cohort study. JAMA 1999; 282:2220–2226.
13. Shiels MS, Cole SR, Wegner S, Armenian H, Chmiel JS, Ganesan A, et al
. Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters. J Acquir Immune Defic Syndr 2008; 48:485–490.
14. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al
. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187–194.
15. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al
. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008; 148:728–736.
16. Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA, Dorfman RF, et al
. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988–1998. Cancer 2003; 98:300–309.
17. Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, et al
. Delayed diagnosis and elevated mortality in an urban population with HIV infection and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006; 43:47–55.
18. Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21:207–213.
19. Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al
. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527–537.
20. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al
. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18:2285–2293.
21. Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, et al
. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 1998; 279:1554–1559.
22. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, et al
. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39:293–299.
23. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681–1691.
24. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002; 138:758–763.
25. Maurer TA, Christian KV, Kerschmann RL, Berzin B, Palefsky JM, Payne D, et al
. Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression. Arch Dermatol 1997; 133:577–583.
26. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24:1383–1388.
27. Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res 2005; 7:511–522.
28. Gritz ER, Vidrine DJ, Lazev AB, Amick BC III, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res 2004; 6:71–77.
29. Stall RD, Greenwood GL, Acree M, Paul J, Coates TJ. Cigarette smoking among gay and bisexual men. Am J Public Health 1999; 89:1875–1878.
30. Karp J, Profeta G, Marantz PR, Karpel JP. Lung cancer in patients with immunodeficiency syndrome. Chest 1993; 103:410–413.
31. Kirk GD, Merlo C, O'Driscoll P, Mehta SH, Galai N, Vlahov D, et al
. HIV infection is associated with an increased risk for lung cancer independent of smoking. J Infect Dis 2007; 45:103–110.
32. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786–3791.
33. Vilchez RA, Finch CJ, Jorgensen JL, Butel JS. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. Medicine (Baltimore) 2003; 82:77–81.
34. Jaffe ES, Lee Harris N, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
35. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99:4283–4297.
36. Dolcetti R, Boiocchi M, Gloghini A, Carbone A. Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur J Cancer 2001; 37:1276–1287.
37. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with 0002030-related immunosuppression in adults. JAMA 2001; 285:1736–1745.
38. Herida A, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, et al
. Incidence of non-0002030-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447–3453.
39. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002; 35:1127–1134.
40. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500–1510.
41. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12:495–503.
42. Palefsky JM, Holly EA, Efirdc JT, Da Costa M, Jay N, Berry JM, Darragh TM. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005; 19:1407–1414.
43. Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, Palefsky JM. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138:453–459.
44. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001; 93:843–849.
45. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, et al
. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203–1211.
46. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS: impact of immunosuppression and incidence trends in the HAART era. J Natl Cancer Inst
47. Nordenvall C, Nyren O, Ye W. Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions. Gut 2006; 55:703–707.
48. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, Jacobson L P. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48:491–499.
49. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006; 43:223–233.
50. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6–S9.
51. Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, et al
, Swiss HIV Cohort Study. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22:2135–2141.
52. McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006; 24:5005–5009.
53. Engels EA, Frisch M, Lubin JH, Gail MH, Biggar RJ, Goedert JJ. Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr 2002; 31:536–541.
54. Giordano TP, Kramer JR, Souchek J, Richardson P, El Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992–2001. Arch Intern Med 2004; 164:2349–2354.
55. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75:347–354.
56. Weber R, Sabin CA, Friis-Moller N, Reiss P, El Sadr WM, Kirk O, et al
. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. Arch Intern Med 2006; 166:1632–1641.
57. Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC, et al
. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100:1584–1589.
58. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al
. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65–73.
59. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al
. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306–1310.
60. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100:56–63.
61. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-0002030-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165:1143–1153.
62. LeBoit PE, Burg G, Weedon D, Sarasain A. World Health Organization Classification of Tumours. Pathology and genetics of skin tumours. Lyon, France: IARC Press; 2006.
63. Gruber SB, Armstrong BK. Cutaneous and ocular melanoma. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology, prevention. New York: Oxford University Press; 2006. pp. 1196–1229.
64. Karagas MR, Weinstock MA, Nelson HH. Keratinocyte carcinomas (basal and squamous cell carcinomas of the skin). In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 2006. pp. 1230–1250.
65. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN. Nonmelanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147:950–956.
66. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, et al
. Incidence and risk factors for the occurrence of non-0002030-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505–1511.
67. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al
. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009; 23:41–50.
68. Overly WL, Jakubek DJ. Multiple squamous cell carcinomas and human immunodeficiency virus infection. Ann Intern Med 1987; 106:334.
69. Lobo DV, Chu P, Grekin RC, Berger TG. Nonmelanoma skin cancers and infection with the human immunodeficiency virus. Arch Dermatol 1992; 128:623–627.
70. Lanoy E, Dores GM, Madeleine MM, Toro JR, Fraumeni JF Jr, Engels EA. Epidemiology of nonkeratinocytic skin cancers among persons with acquired immunodeficiency syndrome in the U.S.AIDS23
71. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319:1096–1100.
72. Moosa MR, Gralla J. Skin cancer in renal allograft recipients: experience in different ethnic groups residing in the same geographical region. Clin Transplant 2005; 19:735–741.
73. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991–998.
74. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921–1926.
75. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 2008; 8:605–615.
76. Agostini C, Sancetta R, Cerutti A, Semenzato G. Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. J Leukoc Biol 1995; 58:495–500.
77. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, et al
. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224–5228.
78. Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 1997; 11:1895–1896.
79. Martin JN, Laker M, Kambugu A, Janka D, Orem J, Mwaka A, et al
. Kaposi's sarcoma-associated immune reconstitution inflammatory syndrome (KS-IRIS) in Africa: initial findings from a prospective evaluation [abstract]. International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies
; Bethesda, Maryland; 2008.
80. Olivero OA. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 2007; 48:215–223.
81. The Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report.Am J Prev Med
82. Wiley DJ, Harper DM, Elashoff D, Silverberg MJ, Kaestle C, Cook RL, et al
. How condom use, number of receptive anal intercourse partners and history of external genital warts predict risk for external anal warts. Int J STD AIDS 2005; 16:203–211.
83. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al
. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000; 284:3040–3042.
84. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118:75S–83S.
85. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al
. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928–1943.
86. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men.Vaccine
87. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008; 197:S279–S293.
88. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum 2008; 51:829–835.
89. Anderson JS, Vajdic C, Grulich AE. Is screening for anal cancer warranted in homosexual men? Sex Health 2004; 1:137–140.
90. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999; 281:1822–1829.
91. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al
. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357:1589–1597.
92. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1–17.
93. Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, Prorok PC, et al
. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer 2005; 47:9–15.
94. Oken MM, Marcus PM, Hu P, Beck TM, Hocking W, Kvale PA, et al
. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst 2005; 97:1832–1839.
95. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al
. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona – 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421–430.
96. Bruno R, Puoti M, Sacchi P, Filice C, Carosi G, Filice G. Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. J Hepatol 2006; 44:S146–S150.
97. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 3 November 2008
. Available at http://aidsinfo.nih.gov/
. [Accessed 24 December 2008]; 2008. U.S. Department of Health and Human Services.